Company Overview

Welcome to NGeneBio

NGeneBio was founded in October 2015 as a joint venture between Genecurix and Korea Telecom, develops in vitro diagnostics (IVD) / companion diagnostics (CDx) products and bioinformatics software (S/W) with cutting-of-edge technologies including next generation sequencing (NGS).

The company launched NGS-based hereditary breast / ovarian cancer panel (BRCAaccuTestTM) with clinical analysis S/W (NGeneAnalysisTM) and received CE-IVD mark in Jun/2017.

NGS panels for solid tumor/hematologic malignancies and BRCA PARP inhibitor CDx test will be launched, inclusive of clinical data analysis SW platform. In support of laboratory medicine community, our mission is to provide clinically validated NGS-IVD / CDx products/services with convergence of innovative biotechnology and bioinformatics.

We have been working on research and development with the cooperation of the anticancer diagnosis project team, domestic and foreign hospitals and biotech companies. We have been striving to secure the technology and develop business model of mid- to long-term perspectives through external patent license-in in addition to the company’s own patent discovery.

We are doing our utmost to achieve our goal of global healthcare service provider based on four core values ​​of challenging execution, respect for life, human resource development and customer trust, and we look forward to your continued support and interest.